Hôpital Ambroise Paré

Marseille

0 studies enrolling now · 2 studies all time

What they study most

Indolent Systemic Mastocytosis, Multiple Myeloma

Studies at this site

• Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis — Completed
• A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma — Stopped early